Firazyr icatibant: Phase III data
Top-line data from the double-blind, international Phase III FAST-3 trial in 88 patients with moderate to very severe cutaneous and/or abdominal symptoms showed that subcutaneous Firazyr met the primary endpoint of significantly reducing the median time to onset of symptom relief for the first attack after enrollment as measured by a 50% reduction in a composite symptom score assessed by the patient vs. placebo (2 vs. 19.8 hours, p<0.001). Firazyr also met the secondary endpoint of significantly reducing the time to onset of symptom relief of the patient's primary symptom as measured by a 30% reduction in symptom score vs. placebo (1.5 vs. 18.5 hours, p<0.001). After the first attack, patients had the option to be treated with open-label Firazyr for subsequent attacks. ...